/
Oncology
Triple-Negative Breast Cancer
107
Pipeline Programs↗
144
Active Trials↗
60
Companies Involved↗
Triple-Negative Breast Cancer is a highly competitive landscape with 107 programs across 60 companies. The most active players are AstraZeneca, Mersana Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd.. 37 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical18
Phase 17
Phase 245
Phase 337
Approved
No programs
Analysis
Modality Breakdown
74%
Small molecule
73 of 99 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 99 classified programs, each share of the total. Modality classified for 93% of 107 pipeline programs.
Analysis
Trial Status
260
clinical trials
Recruiting70 · 27%
Completed49 · 19%
Not yet recruiting42 · 16%
Unknown status36 · 14%
Active, not recruiting31 · 12%
Terminated18 · 7%
Other14 · 5%
Clinical Trials
Trial Activity
260 trials
A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast Cancer
Recruiting·TThe First Affiliated Hospital of Bengbu Medical University·Phase 2·NCT05192798·128 enrolled
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)